Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Study Summary

This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.

Conditions

Neoplasms

Interventions / Drugs

Nenocorilant 200 mg Nenocorilant 300 mg Nenocorilant 400 mg Nivolumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment50 participants

Primary Completion—

Lead SponsorCorcept Therapeutics

Data Retrieved2026-04-11 04:10:22.666697+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.